Literature DB >> 9201802

The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study.

S Kapur1, R Zipursky, P Roy, C Jones, G Remington, K Reed, S Houle.   

Abstract

The purpose of this study was to determine the relationship between dopamine D2 receptor occupancy and plasma haloperidol. Twelve patients treated with 1-5 mg/day of haloperidol had their D2 occupancy measured using [11C]-raclopride and positron emission tomography and haloperidol plasma levels measured using gas chromatograph mass spectrophotometer. The patients exhibited haloperidol plasma levels ranging from 0.5 to 5.8 ng/ml and D2 occupancy from 53 to 88%. The D2 occupancy was related to the plasma level as a saturating rectangular hyperbola relationship (r2 = 0.84) and it showed that, on average, 50% D2 occupancy was achieved with 0.51 ng/ml and 80% D2 occupancy with 2.0 ng/ml. Our findings demonstrate that 2-5 mg/day of haloperidol, which usually leads to plasma levels of 1-2 ng/ml, would be expected to induce 60-80% dopamine D2 receptor occupancy. If, as has been claimed, 70% D2 occupancy is adequate for typical neuroleptic response, then the conventional use of > 10 mg/day may have been too high, since 70% occupancy can be achieved in most patients by 2-5 mg/day. On the other hand, if as others have suggested, 8-12 ng/ml of haloperidol is the correct therapeutic window for plasma levels, then the required therapeutic D2 occupancy is closer to 90%, not 70%. The implications of the D2 occupancy findings for the optimal dosing of neuroleptics are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201802     DOI: 10.1007/s002130050277

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

2.  Elevated DISC1 transcript levels in PBMCs during acute psychosis in patients with schizophrenia.

Authors:  Ann Olincy; Robert House; Bifeng Gao; Peter Recksiek; Tzu Lip Phang; Bernadette Sullivan; Jeff P Hollis; Janet Hopkins; Ted Shade; Michael G Edwards; Ruby Vianzon; Cory Griffiths; John Ceilley; Roger W Helfrich; Jonathan Ritvo; Erica Weis; David Weiss; Judith Gault
Journal:  Transl Biomed       Date:  2011

Review 3.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

4.  The Harms of Antipsychotic Drugs: Evidence from Key Studies.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

5.  Do doctors agree on doses of antipsychotic medications?

Authors:  Johan Schill; Hans Olsson
Journal:  Ther Adv Psychopharmacol       Date:  2016-08-08

6.  Benign hereditary chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation.

Authors:  Takashi Konishi; Satoshi Kono; Masaya Fujimoto; Tatsuhiro Terada; Kozo Matsushita; Yasuomi Ouchi; Hiroaki Miyajima
Journal:  J Neurol       Date:  2012-07-24       Impact factor: 4.849

7.  Effects of dopaminergic modulation on automatic semantic priming: a double-blind study.

Authors:  Christina Andreou; Kristina Veith; Vasilis P Bozikas; Tania M Lincoln; Steffen Moritz
Journal:  J Psychiatry Neurosci       Date:  2014-03       Impact factor: 6.186

8.  Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial.

Authors:  Valerie J Page; E Wesley Ely; Simon Gates; Xiao Bei Zhao; Timothy Alce; Ayumi Shintani; Jim Jackson; Gavin D Perkins; Daniel F McAuley
Journal:  Lancet Respir Med       Date:  2013-08-21       Impact factor: 30.700

9.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.

Authors:  Scot E Purdon; Neil Woodward; Stacy R Lindborg; Emmanuel Stip
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.